When is fecal calprotectin indicated, how should the stool sample be collected, and how are the results interpreted?

Fecal Calprotectin: Indications, Collection, and Interpretation

When to Order Fecal Calprotectin

Fecal calprotectin is indicated primarily for distinguishing inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) in symptomatic patients, and for monitoring disease activity in established IBD patients to guide treatment decisions without requiring colonoscopy. 1, 2

Primary Indications:

Diagnostic Scenarios:

• Symptomatic patients with suspected IBD (abdominal pain, diarrhea, rectal bleeding) to determine need for colonoscopy 3
• Differentiating IBS from IBD when clinical presentation is ambiguous 4, 5

Monitoring Scenarios in Established IBD:

• Patients in symptomatic remission to detect subclinical inflammation and predict flares 1
• Patients with active symptoms to confirm inflammatory activity before treatment escalation 1, 2
• Post-surgical Crohn's disease patients (6-12 months after surgery) to detect endoscopic recurrence 2
• Assessing treatment response and mucosal healing 5

Stool Sample Collection Protocol

Collect the first stool sample of the day from the first bowel movement, taking samples from different parts of the stool, and process or refrigerate within 24 hours to ensure accuracy. 6, 7

Critical Collection Details:

Timing and Sampling:

• First bowel movement of the day provides most reliable results 7
• Sample from 3 different parts of the stool to account for within-stool variability (8-23% variation exists) 7
• If multiple bowel movements occur, the first of the day is most reliable 7

Storage Requirements:

• Process within 24 hours if stored at room temperature (12% decline occurs within 24 hours) 6
• Refrigerate immediately if processing will be delayed beyond 24 hours 6
• Avoid room temperature storage >24 hours as samples become unstable 6

Important Caveats:

• Within-day variability between bowel movements ranges 13-26% depending on cutoff used 7
• Biological variability between measurements is approximately 100% (reference change value), meaning changes <100% may not be clinically significant 6

Interpretation of Results

For diagnostic purposes, use <50 μg/g to rule out IBD (high negative predictive value), and >150 μg/g to rule in IBD; for monitoring established disease, use <150 μg/g to indicate remission and >250 μg/g to confirm active inflammation requiring intervention. 1, 2

Diagnostic Cutoffs (Suspected IBD):

Ruling OUT IBD:

• <50 μg/g: Excellent for excluding IBD (100% sensitivity, 52% specificity, 100% NPV) 4
• Use this threshold in primary care to avoid unnecessary colonoscopies 3
• At this cutoff, distinguishing IBS from IBD shows 93% sensitivity and 94% specificity 3

Ruling IN IBD:

• >150 μg/g: Strong predictor of IBD (87.5% sensitivity, 90.5% specificity) 4
• >250 μg/g: Higher specificity for active inflammation 1

Borderline Zone (50-150 μg/g):

• Represents diagnostic uncertainty 3
• Consider repeat testing before referral 3
• Most patients in this range do not have IBD but require clinical correlation 3

Monitoring Cutoffs (Established IBD):

Ulcerative Colitis:

For Patients in Symptomatic Remission:

• <50 μg/g: Rules out moderate-severe endoscopic inflammation 1
• <150 μg/g: Preferred threshold for monitoring (balances sensitivity/specificity) 1
• <250 μg/g: More specific for excluding active disease 1
• <80 μg/g: Identifies histologic remission (Geboes score ≤3.1) 8
• <50 μg/g: Most clinically relevant for histologic remission (Geboes score ≤2) 8

For Patients with Active Symptoms:

• >50 μg/g, >150 μg/g, or >250 μg/g: Confirms endoscopic inflammation 1
• >123 μg/g: Predicts Mayo endoscopic score >0 (58% sensitivity, 70% specificity) 8
• Higher cutoffs (>250 μg/g) increase specificity for treatment decisions 1

Crohn's Disease:

For Patients in Symptomatic Remission:

• <50 μg/g, <150 μg/g, or <250 μg/g: Rules out endoscopic inflammation 2
• <175 μg/g: Defines small bowel endoscopic remission in patients without colonic lesions 9

For Patients with Active Symptoms:

• >50 μg/g, >150 μg/g, or >250 μg/g: Confirms active inflammation 2

Post-Surgical Monitoring:

• <50 μg/g, <150 μg/g, or <250 μg/g: Rules out postoperative endoscopic recurrence 2
• Test at 6-12 months post-surgery 2

Clinical Context for Interpretation:

Pretest Probability Matters:

• Low pretest probability (asymptomatic UC on stable therapy): ~15% prevalence of moderate-severe inflammation 1
• Intermediate pretest probability (mild symptoms): ~50% prevalence of moderate-severe inflammation 1

Assay-Specific Considerations:

• Different assays (ELISA, CLIA, turbidimetry) may have different optimal cutoffs 6
• ELISA: 120 μg/g optimal threshold 6
• CLIA: 50 μg/g optimal threshold 6
• Turbidimetry: 100 μg/g optimal threshold 6
• Point-of-care tests are as reliable as ELISA but may be less specific 3

Important Limitations and Pitfalls:

False Positives:

• Age ≥65 years: Reduced specificity, calprotectin less reliable 6
• Infectious enteritis: Elevated calprotectin 5
• Colorectal cancer: Elevated calprotectin 5
• NSAIDs, PPIs: May elevate levels 5

False Negatives:

• Isolated small bowel disease: May have lower calprotectin 9
• Proximal Crohn's disease: Less reliable than colonic disease 2

Monitoring Considerations:

• Changes <100% between measurements may reflect biological variability rather than true disease change 6
• Serial measurements more valuable than single values for monitoring 1, 2
• Combine with clinical symptoms for optimal decision-making 1, 2